The week in pharma: action, reaction and insight – week to August 19

tpl-week-in-review-700x466

By Barbara Obstoj-Cardwell. Managing editor

Major research news last week was mixed, with the USA’s Gilead Sciences last Monday releasing positive Phase III data for its Trodelvy in HR+/HER2 metastatic cancer, while France’s Sanofi released disappointing Phase III trial results with its SERD candidate amcenestrant and saying it would discontinue the development program. On the deal-making front, US pharma Merck & Co entered into a collaboration with biotech Orna Therapeutics on the development of multiple vaccines and therapies, paying an upfront $150 million plus pledging milestone and royalties of up to $3.5 billion. Also of note, the US Food and Drug Administration (FDA) last week approved bluebird bio’s beta thalassemia drug Zynteglo, making it the first cell-based gene therapy for this condition.

Trodelvy hits on OS in HR+ mBC

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology